Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Iressa in Metastatic Pancreatic Cancer
NCT00137761Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2004
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib and docetaxel in pancreatic carcinoma, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Response Rate at 3 years. Started Oct 2004; status: completed.
02
Drugs
gefitinibdocetaxel
03
Conditions
pancreatic carcinoma
Beyond the preview
Go deeper on NCT00137761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00137761.